Axxam is proud to announce its participation to the NGN-PET project, that will provide a translational platform of rodent and human neuropathic pain models for the identification and validation of new targets and biomarkers, and suitable for the discovery of new drugs. The project investigates neuron-glia interactions for the identification of novel therapeutic approaches, and for the development of innovative drug screening systems including hiPSC systems.
The IMI2 project was launched on April the 1st and is coordinated by Axxam; the project Leader is ESTEVE supported by Grünenthal GmbH as project Co-Leader.
Axxam coordinates European research project on chronic pain for innovative medicines